Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results
Rhea-AI Summary
Penumbra (NYSE: PEN) provided unaudited, preliminary results for Q4 and full year 2025. Q4 revenue is estimated at $383.0M–$384.8M (+21.4% to +22.0% YoY; +23.2% to +23.8% ex-China). Full-year revenue is estimated at $1,401.3M–$1,403.1M (+17.3% to +17.5% YoY; +24.7% to +24.9% ex-China). Gross margin is ~67.9%–68.1% for Q4 and 67.1% for FY2025. Income from operations is $56.9M–$60.4M (Q4) and $186.9M–$190.4M (FY), implying operating margins of 14.8%–15.7% (Q4) and 13.3%–13.6% (FY).
Positive
- Q4 revenue +21.4% to +22.0% YoY ($383.0M–$384.8M)
- FY 2025 revenue $1,401.3M–$1,403.1M (+17.3% to +17.5% YoY)
- Ex-China FY revenue growth ~24.7% to 24.9%
- FY operating income $186.9M–$190.4M (operating margin 13.3%–13.6%)
Negative
- Reported FY growth reduced to 17.3%–17.5% due to China region impact
- Results are unaudited and preliminary pending final audit
News Market Reaction
On the day this news was published, PEN gained 11.82%, reflecting a significant positive market reaction. This price movement added approximately $1.30B to the company's valuation, bringing the market cap to $12.27B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PEN gained 4.14% with strong preliminary 2025 results while key medical device peers also traded higher (e.g., SNN +2.05%, PODD +2.13%, STE +2.07%), suggesting broader sector strength supporting the move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 29 | Conference appearance | Neutral | -0.2% | Announcement of presentation at 44th J.P. Morgan Healthcare Conference. |
| Nov 19 | Conference appearance | Neutral | -1.2% | Planned presentation at Piper Sandler 37th Annual Healthcare Conference. |
| Nov 05 | Quarterly earnings | Positive | -4.1% | Q3 2025 revenue growth with higher guidance and solid margins. |
| Nov 03 | Clinical trial data | Positive | -0.5% | STORM-PE trial showed superior outcomes for CAVT plus anticoagulation. |
| Oct 27 | Clinical trial data | Positive | -2.0% | Landmark STORM-PE RCT demonstrated CAVT superiority over anticoagulation alone. |
Recent news, including earnings beats and positive clinical data, has often been followed by negative next-day price moves, indicating a pattern of selling into good news.
Over the last six months, Penumbra has reported multiple positive developments, including strong Q3 2025 results with raised full‑year revenue guidance and two favorable STORM-PE trial readouts in Oct–Nov 2025. Despite these fundamentally positive milestones, next‑day price reactions ranged from about -0.2% to -4.06%. Conference appearance announcements in late Nov–Dec 2025 also saw mild negative reactions. This backdrop helps frame today’s preliminary 2025 results as another strong fundamental update against a history of mixed short‑term trading responses.
Market Pulse Summary
The stock surged +11.8% in the session following this news. A strong positive reaction aligns with preliminary 2025 results showing robust revenue growth and margins, such as Q4 revenue of $383.0M–$384.8M and gross margin near 68%. Historical data show mixed short-term trading after good news, so investors might have weighed prior tendencies to sell into strength against the confirmation that full‑year revenue exceeded earlier guidance and operating margins reached the mid‑teens.
AI-generated analysis. Not financial advice.
Unaudited and Preliminary Financial Highlights:
- Fourth quarter 2025 revenue of
$383.0 $384.8 million 21.4% to22.0% compared to the fourth quarter of 2024. Excluding the impact of theChina region, revenue growth was approximately23.2% to23.8% for the fourth quarter 2025. - Revenue of
$1,401.3 million to$1,403.1 million 17.3% to17.5% compared to the full year 2024. Excluding the impact to theChina region, revenue growth was approximately24.7% to24.9% for the full year 2025. - Gross margin of
67.9% to68.1% for the fourth quarter 2025 and67.1% for the full year 2025. - Income from operations of
$56.9 million to$60.4 14.8% to15.7% for the fourth quarter of 2025. - Income from operations of
$186.9 million to$190.4 13.3% to13.6% for the full year 2025.
About Penumbra
Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn and X.
Investor Relations
Penumbra, Inc.
investors@penumbrainc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbra-inc-provides-preliminary-update-on-fourth-quarter-and-full-year-2025-financial-results-302661933.html
SOURCE Penumbra, Inc.
FAQ
What Q4 2025 revenue did Penumbra (PEN) report preliminarily?
What is Penumbra's preliminary full‑year 2025 revenue and growth (PEN)?
How did the China region affect Penumbra's 2025 revenue growth (PEN)?
What gross margin did Penumbra report for FY 2025 (PEN)?
What operating margins did Penumbra report for Q4 and FY 2025 (PEN)?
Are Penumbra's January 15, 2026 results final (PEN)?
